The purpose of this study is to validate the Ottawa score (risk of thromboembolic recurrences) in cancer patients with thromboembolic disease treated with tinzaparin (Innohep®)

The Ottawa score is a clinical predictive score aiming at stratifying thromboembolic recurrences in cancer patients according to identified clinical risk factors and histological type of the tumor. This score has never been validated externally in a prospective way in patients treated with tinzaparin. The objective of this observational prospective study is to enroll cancer patients with TED treated with tinzaparin for a planned period of 6 months and to collect data on thromboembolic recurrences, major hemorrhages, deaths and heparin-induced thrombocytopenia

Inclusion Criteria:

• Cancer patients with histologically confirmed, active or evolving, solid or liquid tumour, or
• Suspected malignant tumour confirmed within a month of index VTE occurrence
• Treated with specific metastatic or adjuvant anti-cancer treatment
• Patients with recent diagnosis of documented symptomatic or incidental VTE and a prescription of tinzaparin for 6 months
• Proximal or distal VTE of lower limbs
• Pulmonary embolism
• Inferior or superior vena cava thrombosis
• Iliac vein thrombosis

Exclusion Criteria:

• Skin cancer other than melanoma
• Life expectancy less than 6 months
• Superficial isolated thrombosis
• Isolated subsegmental pulmonary embolism
• Cerebral, visceral thrombosis
• Superior limbs VTE or Central catheter thrombosis
• Patients being treated with anticoagulants by more than 7 days

Patient population from French general hospitals, anticancer centres, and university hospitals treating more than 1000 cancer patients per year